These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

4805 related items for PubMed ID: 4052966

  • 1. The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines.
    Livingston PO, Kaelin K, Pinsky CM, Oettgen HF, Old LJ.
    Cancer; 1985 Nov 01; 56(9):2194-200. PubMed ID: 4052966
    [Abstract] [Full Text] [Related]

  • 2. Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells.
    Livingston PO, Takeyama H, Pollack MS, Houghton AN, Albino A, Pinsky CM, Oettgen HF, Old LJ.
    Int J Cancer; 1983 May 15; 31(5):567-75. PubMed ID: 6852975
    [Abstract] [Full Text] [Related]

  • 3. Serological response of melanoma patients receiving melanoma cell vaccines. I. Autologous cultured melanoma cells.
    Livingston PO, Watanabe T, Shiku H, Houghton AN, Albino A, Takahashi T, Resnick LA, Michitsch R, Pinsky CM, Oettgen HF, Old LJ.
    Int J Cancer; 1982 Oct 15; 30(4):413-22. PubMed ID: 7141736
    [Abstract] [Full Text] [Related]

  • 4. Serological survey of normal humans for natural antibody to cell surface antigens of melanoma.
    Houghton AN, Taormina MC, Ikeda H, Watanabe T, Oettgen HF, Old LJ.
    Proc Natl Acad Sci U S A; 1980 Jul 15; 77(7):4260-4. PubMed ID: 6933476
    [Abstract] [Full Text] [Related]

  • 5. [Vaccine therapy of malignant melanoma. II. Serological evaluation of the immune responses to the injection using allogeneic melanoma cell vaccine].
    Takeyama H, Watanabe T, Livingston PO.
    Gan To Kagaku Ryoho; 1983 Jul 15; 10(7):1624-33. PubMed ID: 6870307
    [Abstract] [Full Text] [Related]

  • 6. Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody.
    Real FX, Mattes MJ, Houghton AN, Oettgen HF, Lloyd KO, Old LJ.
    J Exp Med; 1984 Oct 01; 160(4):1219-33. PubMed ID: 6237165
    [Abstract] [Full Text] [Related]

  • 7. Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells.
    Livingston PO, Albino AP, Chung TJ, Real FX, Houghton AN, Oettgen HF, Old LJ.
    Cancer; 1985 Feb 15; 55(4):713-20. PubMed ID: 2981601
    [Abstract] [Full Text] [Related]

  • 8. [Serological analysis of melanoma patients receiving autologous melanoma cell vaccines].
    Watanabe T.
    Gan To Kagaku Ryoho; 1983 Feb 15; 10(2 Pt):261-72. PubMed ID: 6881976
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Anti-T antibody in malignant melanoma patients. Influence of response and survival following chemotherapy--changes in serum levels following C parvum, BCG immunization.
    Thatcher N, Hashmi K, Chang J, Swindell R, Crowther D.
    Cancer; 1980 Sep 15; 46(6):1378-82. PubMed ID: 7417939
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line.
    Osanto S, Schiphorst PP, Weijl NI, Dijkstra N, Van Wees A, Brouwenstein N, Vaessen N, Van Krieken JH, Hermans J, Cleton FJ, Schrier PI.
    Hum Gene Ther; 2000 Mar 20; 11(5):739-50. PubMed ID: 10757353
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.
    Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves MJ, Helling F, Ritter G.
    J Clin Oncol; 1994 May 20; 12(5):1036-44. PubMed ID: 8164027
    [Abstract] [Full Text] [Related]

  • 16. Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine.
    Bystryn JC, Henn M, Li J, Shroba S.
    Cancer Res; 1992 Nov 01; 52(21):5948-53. PubMed ID: 1382848
    [Abstract] [Full Text] [Related]

  • 17. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
    Henz BM, Macher E, Bröcker EB, Suciu S, Steerenberg PA, Jung E, Rümke P.
    Dermatology; 1996 Nov 01; 193(2):105-9. PubMed ID: 8884144
    [Abstract] [Full Text] [Related]

  • 18. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
    Chianese-Bullock KA, Pressley J, Garbee C, Hibbitts S, Murphy C, Yamshchikov G, Petroni GR, Bissonette EA, Neese PY, Grosh WW, Merrill P, Fink R, Woodson EM, Wiernasz CJ, Patterson JW, Slingluff CL.
    J Immunol; 2005 Mar 01; 174(5):3080-6. PubMed ID: 15728523
    [Abstract] [Full Text] [Related]

  • 19. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
    Lipton A, Harvey HA, Lawrence B, Gottlieb R, Kukrika M, Dixon R, Graham W, Miller S, Heckard R, Schelzel D, White DS.
    Cancer; 1983 Jan 01; 51(1):57-60. PubMed ID: 6821809
    [Abstract] [Full Text] [Related]

  • 20. Establishment of paired tumor cells and autologous virus-transformed cell lines to define humoral immune responses in melanoma and sarcoma patients.
    Saxton RE, Irie RF, Ferrone S, Pellegrino MA, Morton DL.
    Int J Cancer; 1978 Mar 15; 21(3):299-306. PubMed ID: 204583
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 241.